GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome ... and improvement in some cholesterol parameters, with a very small increase in heart rate.

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Obesity programs: <li /> Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's ...

Of course, there are other forms of GLP-1 agonists but in many of these places it may not be actually the molecule itself and people could be injecting things into themselves and that could be ...

Of course, there are other forms of GLP-1 agonists but in many of these places it may not be actually the molecule itself and people could be injecting things into themselves and that could be ...